ABOUT ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Section A, participants will acquire unique doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. Extra participants are going to be enrolled within the determined monotherapy dosign regimen. In Section B, participants will get oral ruxolitinib and ABBV-744 are going to be supplied as "incorporate-on" therapy. In Segmen